Objective: The goals of this article include the reporting of the epidemiol
ogy, economic and medical impact of allergic rhinitis. In addition, the pha
rmacology and clinical profile of the therapeutic agent cetirizine are revi
ewed.
Data sources: A detailed literature search was conducted. References are li
mited to the English language and human subjects and tissues. Studies consi
dered relevant and important over the past 20 years are highlighted.
Study selection: Prevalence and morbidity data were chosen from more recent
assessments. Because cetirizine is a relatively new compound, studies from
the past several years from peer-reviewed journals have been emphasized.
Results: Allergic rhinitis affects between 15% and 25% of the US general po
pulation. It shares common pathophysiologic mechanisms with conjunctivitis
and asthma and predisposes to nasal infections, otitis media, sinusitis, na
sal polyposis, and orthodontic malocclusions. Direct medical care costs amo
unt to up to 3 billion dollars every year. In addition, the quality of life
of affected individuals is substantially compromised.
Cetirizine is a potent H-1-receptor antagonist and has anti-inflammatory pr
operties. It does not interact with concomitantly administered medications,
has no cardiac adverse effects, and does not appear to be associated with
teratogenicity. Impairment of CNS function is comparable to other low-sedat
ing antihistamines at the recommended dose of 10 mg daily for adults. Its c
linical efficacy for allergic respiratory diseases has been established in
numerous trials.
Conclusions: Allergic rhinitis causes considerable suffering. Cetirizine, w
ith a fine risk-benefit ratio, can be a most valuable therapeutic option.